89bio

Powerful Science – Meaningful Medicines – Changing Lives

San Francisco, United States · Founded 2018 · $60.0M raised

Headquarters
San Francisco
Founded
2018
Business Model
B2B
Website
89bio.com
Total Funding
$60.0M
Last Round
$60.0M Series AOct 2018
Rounds
1

About

89bio is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with liver and cardiometabolic diseases. Its lead candidate, pegozafermin, is an investigational glycopegylated FGF21 analog being evaluated for metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). The company targets FGF21, a metabolic hormone that regulates energy expenditure and glucose and lipid metabolism, as a treatment path for people with these conditions.

Summary

89bio is a Biotech company based in San Francisco, United States, founded in 2018. It has raised $60.0M in total across 1 round, most recently a $60.0M Series A round in Oct 2018.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AOct 2018
$60.0M

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

89bio on Indexed.vc
<a href="https://indexed.vc/companies/89bio"><img src="https://indexed.vc/api/badge/company/89bio" alt="89bio on Indexed.vc" width="260" height="76" /></a>